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The aim of the present study was to investigate whether patients with inflammatory bowel disease (IBD) have 
some degree of renal involvement. Furthermore, we investigated whether this connection is related to active 
bowel disease. In this cross-sectional study, 50 patients diagnosed with IBD, mean age 47.1±16.5 years, 
were recruited from September 2012 to September 2013. The diagnosis of IBD was based on clinical history, 
endoscopic, histological and radiological findings. Disease activity was assessed using the UC activity index 
(UCAI) for ulcerative colitis (UC) and Crohn’s disease activity index (CDAI) for Crohn’s disease (CD). There 
were 38% of UC patients and 62% of CD patients. The prevalence of abnormal albuminuria in UC and CD 
patients was 21.1% and 29%, respectively. There was a high negative correlation between duration of bowel 
disease and 24-h albuminuria in UC patients, as well as a high correlation between albumin-creatinine ratio 
(ACR) and UCAI score in UC patients, but these correlations were not statistically significant, probably due 
to the small number of UC patients. On the other hand, estimated glomerular filtration rate (eGFR) showed 
negative correlation with disease activity in CD patients (r=-0.569; p=0.05), while there was no statistically 
significant correlation between active UC and eGFR (r=0.343; p=NS). In conclusion, abnormal albuminuria is 
quite frequent in patients with IBD. It seems that patients with IBD have some degree of glomerular damage, 
mainly those with CD. Collaborative, prospective studies conducted by gastroenterologists and nephrologists 
are needed to investigate this association.
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INTRODuCTION
Inflammatory bowel diseases (IBD) comprise two types 
of chronic intestinal disorders: Crohn’s disease (CD) and 
ulcerative colitis (uC). CD involves the ileum and co-
lon, but it can affect any region of the intestine, often 
discontinuously. uC involves the rectum and may affect 
part of the colon or the entire colon (pancolitis) in an 
uninterrupted pattern. In CD, the inflammation is often 
transmural, whereas in uC the inflammation is typically 
confined to the mucosa(1).
The extraintestinal manifestations of IBD are common 
and may occur in 25%-40% of patients. Inflammatory 
manifestations in the skin, eyes, liver and joints are 
considered primary manifestations. Development of 
primary extraintestinal manifestation appears to in-
crease the risk of developing a second extraintestinal 
manifestation. Most IBD patients with extraintestinal 
manifestations have colonic inflammation, although 
some patients develop them prior to the onset of co-
lonic symptoms. Extraintestinal manifestations are 
usually present at the time of active phase of IBD(2). 
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In recent years, there have been reports on renal and 
urologic complications of IBD. They were mostly 
found to be related to ureteral obstruction by oxalate 
stones, cystitis, acute tubular necrosis due to volume 
depletion and AA amyloidosis. Nephrolithiasis and 
obstructive uropathy are especially seen with small 
bowel dysfunction(3-5). In a great proportion of IBD 
patients, ureteral obstruction is not caused by stones. 
This noncalculus obstruction can occur in 50%-73% 
of CD patients and 50% of uC patients, and is usu-
ally caused by retroperitoneal local inflammation or 
by surgical complication (sutures) or colon cancer(6). 
There have also been reports of interstitial nephritis, 
mainly due to applied anti-inflammatory therapy, 
such as 5-aminosalicylic acid (5-ASA). Serious renal 
impairment is reported to occur in 1 of 500 patients 
treated with 5-ASA derivative. On the other hand, 
there are some reports that renal tubular damage is an 
extraintestinal manifestation of IBD and not a toxic 
side effect of anti-inflammatory therapy using 5-ASA 
or sulfasalazine(7-10). 
Furthermore, renal failure due to glomerulonephritis 
(GN) caused by the immune complex has been re-
ported in several cases as an extraintestinal manifes-
tation of IBD. The types of immune complex GN that 
have been described due to IBD are membranoprolif-
erative GN, mesangial proliferative GN, membranous 
nephropathy, IgA nephropathy, IgM nephropathy, 
minimal-change disease and antiglomerular basement 
membrane GN. Renal disease occurred in a setting of 
active IBD in many of reported cases. However, the 
question is whether renal disease occurs only related 
to active IBD(6, 11).
According to these observations, the association be-
tween IBD and kidney remains unclear and has to 
be investigated. The aim of the present study was to 
investigate whether patients with IBD (CD and uC) 
have some degree of renal involvement. Furthermore, 
we investigated whether this connection is related to 
active bowel disease and occurs due to the duration of 
bowel disease. 
PATIENTS AND METHODS
In this cross-sectional study, 50 patients diagnosed with 
IBD were recruited from September 2012 to September 
2013. The diagnosis of IBD was based on clinical his-
tory, endoscopic, histological and radiological findings. 
There were 31 (62%) patients with CD and 19 (38%) 
patients with uC. Disease activity was assessed using 
standardized questionnaires. The activity of uC was 
quantified using the uC activity index (uCAI) intro-
duced by Rachmilewitz. A score ≥6 was considered to 
be suggestive of active uC. Furthermore, endoscopic ac-
tivity of uC was also evaluated according to the reliable 
endoscopic index established by other researchers. The 
activity of CD was estimated according to the Best CD 
activity index (CDAI). 
Patients with signs of urinary tract infection, known 
renal disease, hypertension, diabetes mellitus, and use 
of nonsteroidal anti-inflammatory drugs (NSAIDs) or 
other nephrotoxic drugs, patients with a current or re-
cent pregnancy were excluded from this analysis. Fur-
thermore, patients who had morphological changes of 
kidney (proven by ultrasound) were also excluded from 
the study. Extraintestinal manifestations were recorded 
in nine IBD patients. The most common extraintestinal 
manifestation was arthritis. 
Blood samples were analyzed for routine hematologi-
cal and biochemical indices including burn, serum cre-
atinine, liver tests (AST, ALT, GGT and ALP), serum 
iron and ferritin, C-reactive protein (CRP), serum com-
plement C3 and C4, as well as immunoglobulin levels 
by standard clinical chemistry techniques. Estimated 
glomerular filtration rate (eGFR) was calculated ac-
cording to the Modification of Diet in Renal Disease 
(MDRD) formula. Additionally, patients provided 24-h 
urine collection which was used for estimation of albu-
minuria, sodium, potassium, burn and creatinine clear-
ance. In all patients, cytological analysis of urine was 
also performed. urinary albumin concentrations were 
expressed in mg/24h. Albumin-creatinine ratio (ACR) 
was expressed in mg/mmol. Clinical and laboratory data 
were collected at the time of study initiation. 
For this analysis, patients were stratified into two groups 
according to type of IBD into uC and CB groups.
Statistical analysis of data was performed using descrip-
tive statistics (mean and standard deviation). Categorical 
variables were tested by χ2-test or Fisher test. Testing of 
the importance of difference between two independent 
groups was performed using t-test or ANOVA. Pearson 
or Spearman correlation coefficient was used to express 
correlations between variables. The level of statistical 
significance was set at p <0.05. Statistical analysis was 
performed using MedCalc statistical software package, 
version 10 (MedCalc, Mariakerke, Belgium).
RESuLTS
There were 31 patients with CD and 19 patients with uC. 
Of the patients with CD, five had colonic disease, eight 
had ileal disease, and 18 had small and large bowel dis-
ease. Of the patients with uC, six had pancolitis, five 
had left-sided colitis and eight had procto-sigmoiditis. 
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Thirty-one IBD patients had an active bowel disease. 
The mean age of our patients (34 male and 16 female) 
was 47.1±16.5 years and the mean duration of disease 
141±153.4 months. 
First, we were interested to analyze whether there is any 
difference in demographic, clinical and laboratory data 
of our patients with respect to the type of IBD. For this 
analysis, patients were stratified into two groups accord-
ing to the type of IBD: uC and CB groups. Demographic 
and clinical characteristics of the 50 patients according 
to the type of IBD are shown in Table 1A. There was no 
significant between-group difference according to age, 
sex or duration of bowel disease. 
Table 1A
Patient characterisities according to type od inflammatory bowel disease (UC or CD)
CD = Crohn’s disease; uC = ulcerative colitis; CDAI = Best CD activity index;
uCAI = uC activity index; 5-ASA = 5-aminosalicylic acid derivative; NS = nonsignificant
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Characteristic UC (n=19) CD (n=31) p 
Age (yrs) (X±SD) 45.4±10.6 43.4±16.7 NS 
Sex:    
       Male, n (%) 11 (57.9) 23 (74.2) NS 
       Female, n (%)   8 (42.1)   8 (25.8) NS 
CDAI, n (%) / 123.8±51.4  
UCAI (Mayo score), n (%) 5.9±3.4 /  
Duration of disease (months), n (%) 144.2±173.9 135.8±121.2 NS 
Therapy    
         5-ASA, n (%) 8 (42.1) 11 (35.5)  
         Corticosteroid, n (%) 7 (36.8) 10 (32.3)  
         Azathioprine, n (%) 4 (21.1) 15 (48.4)  






Table 1B. Laboratory data according to type of inflammatory bowel disease (UC or CD)  
Characteristic UC (n=19) CD (n=31) p 
CRP (mg/L) 49.3±67.8 48.6±87.3 NS 
Complement C3 1±0.2 1±0.3 NS 
Complement C4 0.2±0.1 0.3±0.1 NS 
IgA 3.1±1 3.1±1.3 NS 
IgM 1.5±0.8 1.2±0.5 NS 
IgG 14±3.7 12.6±4.8 NS 
Serum creatinine (µmol/L) 77.5±22.2 74.1±16.9 NS 
Urea (mmol/L) 3.9±1.4 4.4±1.7 NS 
eGFR (ml/min/1.73 m2) 95.3±30.2 95.2±31.5 NS 
Creatinine clearence (mL/min) 93.4±29.6 104.9±46.2 NS 
Urinary albumin (mg/24 h) 0.1±0.1 0.171±0.2 NS 
ACR (mg/mmol) 7.8±4.7 12.5±16.2 NS 
 
CD = Crohn's disease; UC = ulcerative colitis; CRP = C-reactive protein;  




Laboratory data of our patients are shown in Table 1B. 
The prevalence of albuminuria in uC and CD patients 
was 21.1% and 29%, respectively. Although CD patients 
had higher 24-h albuminuria and ACR, these differences 
were not statistically significant (Table 1B). 
In the next step, we were interested to investigate corre-
lation among various renal tests and clinical data in IBD 
patients. There was a high negative correlation between 
duration of bowel disease and 24-h albuminuria in uC pa-
tients, but this correlation was not statistically significant, 
probably due to the small number of uC patients (Table 2A). 
Table 2B shows correlation between ACR and clinical 
data in uC and CD patients. There was a high corre-
lation (r=0.737) between ACR and MCS score in uC 
patients, although it was not statistically significant 
(p=0.09), probably due to the small number of patients.
On the other hand, eGFR showed a statistically signifi-
cantly negative correlation with disease activity in CD 
patients (r=-0.569; p=0.05). Also, statistical significance 
was almost reached in the correlation between eGFR 
and duration of bowel disease in CD patients (r=-0.391; 
p=0.09) (Table 2C).  
DISCuSSION
Extraintestinal manifestations of IBD are common and 
probably reflect systemic inflammation, autoimmune 
susceptibility, metabolic and nutritional derangement, or 
drug-related toxicity(12,13). In our study, there was a high 
negative correlation between duration of bowel disease 
and 24-h albuminuria in uC patients, as well as high cor-
relation between ACR and MCS score in uC patients, but 
these correlations were not statistically significant, prob-
ably due to the small number of uC patients. Also, eGFR 
showed a statistically significant negative correlation with 
disease activity in CD patients. Statistical significance 
was almost reached in the correlation between eGFR and 
duration of bowel disease in CD patients. We suppose that 
by increasing the number of uC and CD patients, all these 
correlations would reach statistical significance. 
The first two reports of glomerulonephritis in association 
with IBD appeared in the European literature in 1976(14,15). 
Kidney disease as a complication of IBD has been the 
subject of case reports until recently. In 2014, Ambruzs et 
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Table 2A
Correlation between 24-h albuminuria and clinical data in UC and CD patients
al.(12) published a case series examining IBD and kidney 
disease. This was the largest clinicopathologic series to 
date on this topic. They evaluated a large series of kidney 
biopsy specimens from patients with IBD (45 CD cases 
and 38 uC cases). The most common indication for kidney 
CD = Crohn's disease; uC = ulcerative colitis; CRP = C-reactive protein;
eGFR = estimated glomerular filtration rate; ACR = albumin-creatinine ratio;
NS = nonsignificant; data are presented as x+–SD
CD = Crohn’s disease; uC = ulcerative colitis; CDAI = Best CD activity index; uCAI = uC activity index;
NS = nonsignificant
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biopsy in their analysis was acute or chronic kidney 
failure and nephrotic-range proteinuria. IgA nephropathy 
was the most common diagnosis, followed by interstitial 
nephritis, arterionephrosclerosis, acute tubular injury, 
proliferative GN and minimal-change disease.
Table 1B




Table 1B. Laboratory data according to type of inflammatory bowel disease (UC or CD)  
Characteristic UC (n=19) CD (n=31) p 
CRP (mg/L) 49.3±67.8 48.6±87.3 NS 
Complement C3 1±0.2 1±0.3 NS 
Complement C4 0.2±0.1 0.3±0.1 NS 
IgA 3.1±1 3.1±1.3 NS 
IgM 1.5±0.8 1.2±0.5 NS 
IgG 14±3.7 12.6±4.8 NS 
Serum creatinine (µmol/L) 77.5±22.2 74.1±16.9 NS 
Urea (mmol/L) 3.9±1.4 4.4±1.7 NS 
eGFR (ml/min/1.73 m2) 95.3±30.2 95.2±31.5 NS 
Creatinine clearence (mL/min) 93.4±29.6 104.9±46.2 NS 
Urinary albumin (mg/24 h) 0.1±0.1 0.171±0.2 NS 




Table 2A. Correlation between 24-h albuminuria and clinical data in UC and CD patients 
 UC (n=19)  (n=31) 
  r p r p 
UCAI 0.304 NS / / 
CDAI / / 0.171 NS 
Duration of bowel disease (months) -0.509 NS -0.125 NS 
 
CD = Crohn's disease; UC = ulcerative colitis; CDAI = Best CD activity index; UCAI = UC activity index;  
NS = nonsignificant 
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Table 2B. Correlation between albumin-creatinine ratio and clinical data in UC and CD 
patients 
 UC (n=19) CD (n=31) 
  r p r p 
UCAI 0.737 0.09 / / 
CDAI / / -0.093 NS 
Duration of bowel disease (months) -0.221 NS -0.051 NS 
 
CD = Crohn's disease; UC = ulcerative colitis; CDAI = Best CD activity index; UCAI = UC activity index;  
NS = nonsignificant 
 
 
 UC (n=19) CD (n=31) 
  r p r p 
UCAI 0.737 0.09 / / 
CDAI / / -0.093 NS 
Duration of bowel disease (months) -0.221 NS -0.051 NS 
 
 
Table 2C. Correlation between estimated glomerular filtration rate and clinical data in UC and 
CD patients 
 UC (n=19) CD (n=31) 
  r p r p 
UCAI 0.165 NS / / 
CDAI / / -0.569 0.05 
Duration of bowel disease (months) -0.315 NS -0.391 0.09 
 
CD = Crohn's disease; UC = ulcerative colitis; CDAI = Best CD activity index; UCAI = UC activity index;  
NS = nonsignificant 
 
 
 UC (n=19) CD (n=31) 
  r p r p 
UCAI 0.165 NS / / 
CDAI / / -0.569 0.05 
Duration of bowel disease (months) -0.315 NS -0.391 0.09 
 




Correlation between estimated glomerular filtration rate and clinical data in UC nad CD patients
The exact mechanism linking IBD and kidney is still poor 
understood. Recent investigations have highlighted the 
close relationship between the kidney and gastrointestinal 
(GI) tract, a term frequently referred to as the kidney-gut 
axis in patients with chronic kidney disease. According 
to data, two important pathophysiological concepts have 
evolved. The first refers to the production and accumula-
tion of toxic end-products derived from increased bacte-
rial fermentation of protein and other nitrogen-containing 
substances in the GI tract. The second refers to transloca-
tion of endotoxins and live bacteria from gut lumen into 
the bloodstream due to damage to the intestinal epithelial 
barrier and quantitative/qualitative alterations of the in-
testinal microbiota associated with the uremic milieu. In 
both cases, these gut-centered alterations may have rel-
evant systemic consequences in chronic kidney disease 
patients, since they are able to trigger chronic inflam-
mation(16). Some animal and human studies suggest that 
prebiotics and probiotics may have therapeutic roles in 
maintaining a metabolically-balanced gut microbiota 
and reducing progression of chronic kidney disease and 
uremia-associated complication in these patients(17). Addi-
tionally, an increasing number of reports have associated 
mucosal inflammation or infection with IgA nephropa-
thy. Thus, IgA nephropathy in IBD probably represents 
a complex interplay of mucosal inflammation, loss of an-
tigenic exclusion, and tolerance, chronic immune stimu-
lation, and dysregulated IgA production and transport(12, 
18). On the other hand, there is growing evidence related 
to genetics, intestinal microbiota composition, and the 
immune system factors such as precursors for the initia-
tion and progression of intestinal conditions. The use of 
certain probiotic microorganisms has been touted as a 
possible and promising therapeutic approach in reducing 
the risk of IBD, specifically uC(19, 20). According to these 
observations, immune mechanism and gut microbiota are 
probably the pathogenic links between IBD and glomeru-
lonephritis, but further studies are warranted on this topic. 
Tubulointerstitial injury can also result from an indirect 
response through the induction of systemic inflammatory 
or immune reactions. Some animal and human studies 
support the role of immune-mediated mechanisms in tu-
bulointerstitial nephritis(9). 5-ASA is currently the treat-
ment of choice for IBD patients. It can be administered 
as sulfasalazine (5-ASA+sulfapyridine) or mesalazine 
(5-ASA+gel resins)(6). Most reported cases of tubulointer-
stitial nephritis in IBD occurred in patients treated with 
5-ASA derivatives, which have known nephrotoxic ef-
fects. The exact mechanism is not fully understood, but 
some authors support the idea that it probably represents 
an idiosyncratic, delayed-type hypersensitivity that is in-
dependent of dose and duration of exposure(17). However, 
there are some reports that renal tubular damage is an 
extraintestinal manifestation of IBD rather than a toxic 
side effect of anti-inflammatory therapy using 5-ASA or 
sulfasalazine. This appears to be more common in CD 
than in uC. According to these studies, it is possible that 
interstitial nephritis as an extraintestinal manifestation of 
IBD is maybe secondary to systemic immune dysregula-
tion and cytokine activation(6-10, 17).
Although our study had several limitations such as ob-
servational study design, relatively small number of 
patients, absence of kidney biopsy, and the fact that pa-
tient and renal disease outcomes were not examined, it 
still raised a number of unanswered questions related to 
kidney function monitoring and outcome in patients with 
uC and CD. First, what is the exact risk of developing 
renal complications in IBD patients? Second, what kidney 
function markers correlate best with IBD activity or what 
patient clinical data would help us better identify those 
IBD patients that are at a higher risk of developing kidney 
complications, including drug-related nephrotoxicity? 
Third, how often should kidney function be monitored in 
patients with IBD? Are there some urinary markers which 
may indicate early renal impairment in IBD patients? Fi-
nally, could probiotics become a useful treatment option 
for kidney complications in IBD patients? Collaborative 
studies by gastroenterologists and nephrologists should 
help provide answers to these questions. 
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SAŽETAK
uPALNA BOLEST CRIJEVA I BuBREG – POSTOJI LI POVEZANOST?
I. MIKOLAšEVIć1,2, S. MILIć2, B. MIJANDRušIć-SINčIć2, V. LuKENDA ŽANKO3, I. JELIć 
PRANJIć1, V. MAVRINAC2 , I. KRZNARIć-ZRNIć2, S. RAčKI1, D. šTIMAC2 i L. ORLIć1
 Klinički bolnički centar Rijeka,
1Klinika za nefrologiju, dijalizu i transplantaciju bubrega,
2Klinika za gastroenterologiju, Rijeka i
3Opća bolnica “Dr. Josip Benčević”, Odjel za internu medicinu, Slavonski Brod, Hrvatska
Cilj ove studije bio je ispitati imaju li bolesnici s upalnom bolesti crijeva u nekoj mjeri promjene na bubregu. Što-
više, ispitivali smo odnosi li se ta povezanost na aktivnu bolest crijeva. U ovoj presječnoj studiji okupili smo od 
rujna 2012. do rujna 2013. godine 50 bolesnika srednje dobi od 47,1±16,5 godina s dijagnozom upalne bolesti 
crijeva postavljenom na osnovi anamneze, endoskopskih, histoloških i radioloških nalaza. Aktivnost bolesti pro-
cjenjivali smo indeksom aktivnosti ulceroznog kolitisa (UC activity index, UCAI) i indeksom za Crohnovu bolest 
(Crohn’s disease index, CDAI). Bilo je 38% bolesnika s ulcertivnim kolitisom (UK) i 62% bolesnika s Crohnovom 
bolešću (CB). Učestalost abnormalne albuminurije bila je 21,1% u bolesnika s UK i 29% u onih s CB. Nađena 
je visoka negativna korelacija između trajanja bolesti crijeva i 24-h albuminurije u bolesnika s UK, kao i visoka 
korelacija između odnosa albumin-kreatinin (ACR) i zbira UCAI u bolesnika s UK, ali te korelacije nisu bile 
statistički značajne, vjerojatno zbog malog broja bolesnika s UK. S druge strane, procijenjena stopa glomeru-
larne filtracije (estimated glomerular filtration rate, eGFR) pokazala negativnu korelaciju s aktivnošću bolesti 
u bolesnika s CB (r=-0,569; p=0,05), dok nije bilo statistički značajne korelacije između UK i eGFR (r=0,343; 
p=NS). Zaključujemo da je abnormalna albuminurija dosta česta u bolesnika s upalnom bolesti crijeva. Čini 
se da bolesnici s tom bolešću imaju do neke mjere oštećenje glomerula, pretežito oni s CB. Da se istraži ta 
povezanost potrebne su zajedničke prospektivne studije gastroenterologa i nefrologa.
Ključne riječi: upalna bolest crijeva, ekstraintestinalne manifestacije, bubreg
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